Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review

Background: researchers and sponsors increasingly confront the issue of whether participants in a clinical trial should have post-trial access (PTA) to the trial drug. Legislation and guidelines are inconsistent, ambiguous or silent about many aspects of PTA. Recent research highlights the potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Sofaer, Neema, Strech, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133737/
https://www.ncbi.nlm.nih.gov/pubmed/21754950
http://dx.doi.org/10.1093/phe/phr013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133737/
https://www.ncbi.nlm.nih.gov/pubmed/21754950
http://dx.doi.org/10.1093/phe/phr013

Ejemplares similares